智通财经网·2025-10-26 07:59Core Insights - WuXi AppTec (603259.SH) reported a revenue of 32.857 billion yuan for the first three quarters of 2025, representing a year-on-year growth of 18.61% [1] - The net profit attributable to shareholders reached 12.076 billion yuan, with a significant year-on-year increase of 84.84% [1] - The net profit excluding non-recurring gains and losses was 9.522 billion yuan, reflecting a year-on-year growth of 42.51% [1] Chemical Business - The chemical business generated revenue of 25.98 billion yuan, marking a year-on-year increase of 29.3% [1] - The small molecule drug discovery ("R") business has successfully synthesized and delivered over 430,000 new compounds for clients in the past twelve months [1] - The company has converted 250 molecules from research to development (R to D) in the first three quarters of 2025 [1] Small Molecule Development and Manufacturing - The small molecule development and manufacturing (D&M) business reported revenue of 14.24 billion yuan, showing a year-on-year growth of 14.1% [2] - A total of 621 new molecules were added to the small molecule D&M pipeline in the first three quarters of 2025, bringing the total to 3,430, which includes 80 commercial projects and 87 clinical phase III projects [2] - The company successfully passed FDA inspections at its Changzhou and Taixing API bases with zero defects in March 2025 [2] TIDES Business - The TIDES business (oligonucleotides and peptides) experienced rapid growth, with revenue reaching 7.84 billion yuan, a year-on-year increase of 121.1% [3] - As of September 2025, TIDES orders on hand grew by 17.1% year-on-year, with the number of clients served increasing by 12% and the number of molecules served rising by 34% [3] - The company completed the capacity expansion for peptides in Taixing ahead of schedule, increasing the total volume of solid-phase synthesis reactors to over 100,000 liters [3]